Ranibizumab: 10 agencies, 2006–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 19.7 years separate the first record, 22 Nov 2006 at TLV (Sweden), from the most recent, 2026 at PBAC (Australia).
CONITEC (Brazil) changed its position: not recommended on 26 Nov 2012, recommended by 21 Sep 2020, after a resubmission.
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for ranibizumab, 2 submissions were never made and 4 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 5 of 41 records date from 2023 or later.
The programme is broad: 12 distinct indication wordings are recorded for ranibizumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
7 of these 41 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
TLV (Sweden) was first to assess ranibizumab, on 22 Nov 2006; NYE METODER (Norway) did not open a file until 22 Oct 2023 — an unusually long tail of 16.9 years between the earliest and latest system to look at it.
The record arrives in waves: 8 separate years each carry two or more decisions, spread across 16 years in total.
9 of the 10 agencies here assessed ranibizumab more than once, PBAC (Australia) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
10 of the 18 agencies in this archive hold a record for ranibizumab.
The full ledger for ranibizumab reads 13 recommended, 9 other, 4 deferred to NICE and 4 restricted, with 11 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2025 | Proliferative diabetic retinopathy (PDR) | Recommended | source |
| NYE METODER (Norway) | 27 Apr 2025 | Behandling av retinopati hos premature spedbarn | decision recorded | source |
| HAS (France) | 7 Jul 2021 | Re-assessment following post-listing study results | SMR substantial · ASMR V | source |
| NICE (England) | 30 Jun 2020 | NICE TA637 | terminated appraisal | source |
| CONITEC (Brazil) | 10 Apr 2015 | Degeneração macular relacionada à idade exsudativa | not incorporated | source |
36 further decisions for ranibizumab, across 10 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 21 further source documents.
Related molecules
- brolucizumab — divergent outcome (recommended vs not recommended) on a shared indication
- faricimab — same ATC class S01L — Ophthalmologicals
- sotorasib — also decided by NYE METODER in 2025Q2
- vutrisiran — also decided by NYE METODER in 2025Q2
- bosutinib — also decided by NYE METODER in 2025Q2
- tocilizumab — also decided by NYE METODER in 2025Q2
Coverage: 41 decisions for ranibizumab from 10 agencies, 2006 to 2026. Data to 7 Sep 2026. ATC class S01L — Ophthalmologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.